Bookmark and Share
BioAssay: AID 560

Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)

Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA) ..more
_
   
 Tested Compounds
 Tested Compounds
All(64907)
 
 
Active(979)
 
 
Inactive(63929)
 
 
 Tested Substances
 Tested Substances
All(64925)
 
 
Active(979)
 
 
Inactive(63946)
 
 
AID: 560
Data Source: The Scripps Research Institute Molecular Screening Center (RORA_AG_Lumi_1536_%ACT)
BioAssay Type: Primary, Primary Screening, Single Concentration Activity Observed
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2006-12-18
Modify Date: 2007-04-11

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 979
Related Experiments
Show more
AIDNameTypeComment
675Counterscreen for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1): A cell-based dose-response assay for inhibition of the RAR-related orphan receptor A (RORA)Confirmatorydepositor-specified cross reference
681Dose-response cell-based assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)Confirmatorydepositor-specified cross reference
692Dose-response cell-based assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)Confirmatorydepositor-specified cross reference
695Counterscreen for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA): A cell-based dose-response assay for inhibition of the Steroidogenic Factor 1 (SF-1)Confirmatorydepositor-specified cross reference
1000Screening for Inhibitors of the Mevalonate Pathway in Streptococcus Pneumoniae - MK Secondary AssayConfirmatorydepositor-specified cross reference
1951Summary of probe development efforts to identify activators of the nuclear receptor Steroidogenic Factor 1 (SF-1).Summarydepositor-specified cross reference
1954Summary of probe development efforts to identify activators of the Retinoic Acid Receptor-related orphan receptor A (RORA).Summarydepositor-specified cross reference
522Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)Screeningsame project related to Summary assay
522Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)Screeningsame project related to Summary assay
Description:
Source (MLSCN Center Name): The Scripps Research Institute Molecular Screening Center
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Orphagen Pharmaceuticals, San Diego, CA
Network: Molecular Library Screening Center Network (MLSCN)
Grant Proposal Number: 1X01-MH077624-01

External Assay ID: RORA_AG_Lumi_1536_%ACT

Name:
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)

Description:
Nuclear receptors are a family of small molecule and hormone-regulated transcription factors that share conserved DNA-binding and ligand-binding domains. Small pharmacological compounds able to bind to the cleft of the ligand-binding domain could alter its conformation and subsequently modify transcription of target genes. Such ligand agonists and/or antagonists have already been successfully designed for 23 nuclear receptors among the 48 previously identified in the human genome [1-3].
RORA is one of three related orphan nuclear receptors, including RORB and RORC, known as "Retinoic Acid Receptor-related orphan receptors" [4].
RORA has unusual potential as a therapeutic target for "metabolic syndrome". This refers to a convergence of pathogenic factors, including insulin resistance, dyslipidemia, hypertension, and a proinflammatory state, that greatly elevate the risk of diabetes and atherosclerosis [5]. RORA has been shown to be implicated in several key aspects of this pathogenesis. For instance, the staggerer mouse, which carries a homozygous germline inactivation of RORA, shows low body weight, high food consumption [6-8], elevated angiogenesis in response to ischemia [9], susceptibility to atherosclerosis [8], and an abnormal serum lipid profile [10]. A combination of genetic and cellular studies also showed that RORA regulates lipoprotein levels and very likely has an impact on circadian rhythm and metabolism in peripheral tissue such as the liver.
Taken together, those observations highlight the need to identify specific ligands of RORA that could help understand its therapeutic potential and provide good chemical starting points for further drug development.

References:

[1]#Evans RM. The nuclear receptor superfamily: a rosetta stone for physiology. Mol Endocrinol 19:1429-1438, 2005.
[2]#Kliewer SA, Lehmann JM, and Willson TM. Orphan nuclear receptors: shifting endocrinology into reverse. Science 284: 757-760, 1999.
[3]#Li Y, Lambert MH, and Xu HE. Activation of nuclear receptors: a perspective from structural genomics. Structure (Camb) 11: 741-746., 2003.
[4]#Jetten AM, Kurebayashi S, and Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 69: 205-247, 2001.
[5]#Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 24: e13-18, 2004.
[6]#Bertin R, Guastavino JM, and Portet R. Effects of cold acclimation on the energetic metabolism of the staggerer mutant mouse. Physiol Behav 47: 377-380, 1990
[7]#Guastavino JM, Bertin R, and Portet R. Effects of the rearing temperature on the temporal feeding pattern of the staggerer mutant mouse. Physiol Behav 49: 405-409, 1991
[8]#Mamontova A, Seguret-Mace S, Esposito B, Chaniale C, Bouly M, Delhaye-Bouchaud N, Luc G, Staels B, Duverger N, Mariani J, and Tedgui A. Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circulation 98: 2738-2743., 1998
[9]#Besnard S, Silvestre J-S, Duriez M, Bakouche J, Lemaigre-Dubreuil Y, Mariani J, Levy BI, and Tedgui A. Increased ischemia-induced angiogenesis in the staggerer mouse, a mutant of the nuclear receptor RORa. Circ Res 89: 1209-1215, 2001.
[10]#Raspe E, Duez H, Gervois P, Fievet C, Fruchart J-C, Besnard S, Mariani J, Tedgui A, and Staels B. Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalpha. J Biol Chem 276: 2865-2871, 2001.

Keywords:
RAR-related orphan receptor A, RORA, nuclear receptor, RZRA, ROR1, ROR2, ROR3, NR1F1, transcriptional assay, CHO-K1, luciferase, luminescence, Scripps, primary, activation
Protocol
Assay Overview:
The transcriptional cell-based assay utilizes a fusion of the DNA-binding domain of the yeast transcriptional factor Gal4 with the ligand-binding domain of target receptor RORA (encoded by the pFA-hRORA plasmid, Orphagen Pharmaceuticals) to regulate a luciferase reporter containing 5xGal4 response elements at its promoter region (pG5-luc, Stratagene). Both pFA-hRORA and pG5-luc plasmids are transiently co-transfected in CHO-K1 (Chinese Hamster Ovary) cells. The presence in this cell line of required co-activators allows the expression of luciferase driven by activated RORA nuclear receptors. Compounds that inhibit the basal transcription of luciferase are detected through the suppression of light emission using the SteadyLite luciferase detection kit (Perkin Elmer). Such compounds hence constitute potential inhibitors of the RORA nuclear receptor.
The primary HTS assay was conducted in 1536-well format. All compounds were tested once at a 10 micromolar final concentration.
Protocol Summary:
Six million CHO-K1 cells were seeded in T-175 flasks (Corning part#431080) containing 20 milliliters of F12 media (Invitrogen part#31765-092) supplemented with 10% v/v fetal bovine serum (Gemini part#900-108) and 1% v/v penicillin-streptomycin-neomycin mix (Invitrogen part#15640-055). Flasks were then incubated for 20 hours at 37 degrees Celsius, 5%CO2 and 95% relative humidity.
The following day, CHO-K1 cells were transiently transfected with the pG5-luc reporter plasmid (Stratagene) and the RORA/Gal4 fusion expressing plasmid (pFA-hRORA, Orphagen Pharmaceuticals). Transfection was performed using the TransIT-CHO transfection kit (Mirus part#2176) according to the manufacturer's protocol.
Flasks were designated +RORA or -RORA. +RORA flasks received 1.2 milliliters of F12 media containing 54 microliters of TransIT CHO reagent (Mirus), 9 microliters of CHO Mojo reagent (Mirus), 9 ug of pG5-luc (Stratagene), 8.75 ug of empty pcDNA3.1 (Invitrogen), and 125 ng of pFA-hRORA plasmid (Orphagen Pharmaceuticals).
-RORA designated flasks received exactly the same transfection reagents and DNA excepting plasmid pFA-hRORA.
Flasks were then placed back in the incubator at 37 degrees Celsius, 5%CO2 and 95% relative humidity.
Four hours after transfection, cells were trypsinized and suspended to a concentration of 800,000 cells per milliliter in F12 media (Invitrogen part#31765-092) supplemented with 10% v/v heat inactivated fetal bovine serum (Gemini part#900-108) and 1% v/v penicillin-streptomycin-neomycin mix (Invitrogen part#15640-055).
The assay began by dispensing 5 microliters of cell suspension to each well (i.e. 4,000 cells/well) of a white solid-bottom 1536-well plate. Cells from flasks designated -RORA were seeded in the first two columns of the 1536-well plate (mock-transfected positive control) and the remaining 46 columns were filled with +RORA cells.
One hour after seeding, +RORA cells were treated with 50 nL/well of test compounds (i.e. 10 micromolar) or DMSO (negative control) and -RORA cells with 50nL/well of DMSO (positive control). Plates were then placed in the incubator at 37 degrees Celsius, 5% CO2 and 95% relative humidity.
Twenty hours later, plates were equilibrated to room temperature for 20 minutes. A luciferase assay was performed by adding 5 microliters per well of the SteadyLite HTS reagent (Perkin Elmer part#6016989). After a 15 minutes incubation time, light emission was measured with the ViewLux reader (Perkin Elmer).
The percent activation of each compound has been calculated as follows:
%activation = 100 x (( RLU_compound - Median_RLU_negative_control ) / ( Median_RLU_negative_control - Median_RLU_background ))
with background: -RORA cells treated with 1% DMSO
and negative control: +RORA cells treated with 1% DMSO
A mathematical algorithm was used to determine nominally active compounds.
Two values were calculated: (1) the average percent activation of all compounds tested, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater %activation than the cutoff parameter was declared active.
The reported Pubchem_Activity_Score has been normalized to 100% of the highest observed primary activation. Negative % activation values are reported as activity score zero.
Comment
All data reported were normalized on a per-plate basis.
Possible artifacts of this assay can include, but are not limited to:
compounds that induce cell proliferation, compounds that increase luciferase activity, compounds that activate transcriptional activity.
Categorized Comment - additional comments and annotations
From PubChem:
Assay Format: Cell-based
Assay Cell Type: CHO-K1
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1%ACTIVATIONNormalized percent activation of the primary screen at a compound concentration of 10 micromolar.Float

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: